Nuvectra

Quote
























anonymous said:
hopefully we get bought soon, Stryker would be great, and they can inject some capital and leadership

This place still has great potential!
Click to expand...

If the rumors around RE: recharging are remotely true, why would ANY company with deep pockets take on the potential liability associated with this product line? If you buy a business, you also buy their problems. Medtronic bought Kyphon, for instance, and got a Consent Decree while they were at it!!
 






anonymous said:
If the rumors around RE: recharging are remotely true, why would ANY company with deep pockets take on the potential liability associated with this product line? If you buy a business, you also buy their problems. Medtronic bought Kyphon, for instance, and got a Consent Decree while they were at it!!
Click to expand...
big question is if recharging issues are isolated to peripherals or implant. externals are obviously easier to replace and correct. faster redesign cycle as well. MAUDE doesn’t have much on explants due to inability to recharge. if explanted it should be on maude. complaints for the external device replacement due to not working wouldn’t go on maude
 






Does a consent decree shut the activities down of all products that are selling and being promoted or is it issued because just a particular product has failed to perform and only affects that specific product?
 






Private Equity can take this private for 100mm clean up a few minor issues wait for Algovita full-body MRI compatibility slap a new name on it and take it public at a 300 to 400mm market cap. Just Saying !
 






anonymous said:
big question is if recharging issues are isolated to peripherals or implant. externals are obviously easier to replace and correct. faster redesign cycle as well. MAUDE doesn’t have much on explants due to inability to recharge. if explanted it should be on maude. complaints for the external device replacement due to not working wouldn’t go on maude
Click to expand...

Issues are isolated to the peripherals. There is no question about that. I know this first hand.
IPG is a bit to power hungry but the PPC and charging paddle are the entire reason charging is painful for the patients. You could say the IPG is a bit too power hungry but there are fixes for that which would only take some capital and competent technical leadership, something Nuvectra literally has never had.
 






I'd like to see you guys make it, regardless of going it alone or if you are acquired. I think its better for patients and providers to have more choices in their therapy options. The product was always good, it just never had the guidance to make it great. Bring in solid leadership, correct the issues, raise some cash, and keep it going forward. Hays can keep the commercial team going, but I do think their should be a better CEO at the helm to support him and the remaining peeps.
 






anonymous said:
I'd like to see you guys make it, regardless of going it alone or if you are acquired. I think its better for patients and providers to have more choices in their therapy options. The product was always good, it just never had the guidance to make it great. Bring in solid leadership, correct the issues, raise some cash, and keep it going forward. Hays can keep the commercial team going, but I do think their should be a better CEO at the helm to support him and the remaining peeps.
Click to expand...
as a shareholder i’d like to see them make it... as a family member of a patient with a nuvectra scs i’d like to get their charging shit together and survive so their implant is supported
 






anonymous said:
I'd like to see you guys make it, regardless of going it alone or if you are acquired. I think its better for patients and providers to have more choices in their therapy options. The product was always good, it just never had the guidance to make it great. Bring in solid leadership, correct the issues, raise some cash, and keep it going forward. Hays can keep the commercial team going, but I do think their should be a better CEO at the helm to support him and the remaining peeps.
Click to expand...


I think the market is pivoting to evidence. Big players are spending $$$$ generating it. RCTs aren’t cheap and customers are going to begin expecting them. I really think y’all overestimate NVTR’s staying power. It’s a me-too product in a crowded space that’s primary selling points (stretchy leads and 24 contacts) aren’t particularly compelling without evidence to support why they matter. That, plus a reputation for recharging issues and ... good luck.
 






anonymous said:
Does a consent decree shut the activities down of all products that are selling and being promoted or is it issued because just a particular product has failed to perform and only affects that specific product?
Click to expand...
uhhhhh nuvectra only has the one product. consent decrees are usually negotiated but usually have a significant impact on getting new devices approved and operations. may involve a field action (recall). a consent decree is usually for some seriously nefarious shit, systemic quality system issues, and failure to respond to 483s
 












anonymous said:
uhhhhh nuvectra only has the one product. consent decrees are usually negotiated but usually have a significant impact on getting new devices approved and operations. may involve a field action (recall). a consent decree is usually for some seriously nefarious shit, systemic quality system issues, and failure to respond to 483s
Click to expand...

Thank you for the explanation!
 












The reason they won't get a consent decree is their problems are just giant money pits but are not impacting patient safety.

Some of us have known for years this company was going to fail because management was unimaginably out of touch with the reality of how bad the charger and other peripherals were. Somehow the cost impact was either hidden or not visible to the board otherwise Drees and Norbert never would have been allowed to waste so much time on DBS (Aleva) and a bunch of other BS.

I told a board member that many of us have known how bad it was for years before things were finally trying to be fixed by technical leadership. He had quite a dumbfounded look on his face. I don't think any of them knew how bad the quality issues were until it was (possibly) too late.

Let's just say there was a building full of experienced medical device professionals who have been disgusted at how incompetent technical leadership was. It was not being run like what they were used to at profitable, established companies. Most left in disgust for real jobs at profitable companies. Now the bad leaders are almost all gone and replacements get it but it's probably too late. The incompetence of their former management is legendary in a certain pair of cities area where lots of med device companies reside.
 


















anonymous said:
What is a 483
Click to expand...
It’s the form number that the FDA fills out after they visit you if they need to tell you that your shits all fucked up and retarded.

You can literally type “what is a 483” in google and it tells you. you don’t even need to know that dog is on the left. Do you work for Nuvectra quality group or are you just lazy?
 






Top Bottom
Back
Quote